Romanian 1024 * 768 / small 1024 * 768 / big 1280 * 1024 / small 1280 * 1024 / big
Pagina principala Pagina principala Pagina principala
Shop Cauta Articol
Alimente Acide Alcaline Alimente Acide Alcaline
Alimente Wight Loss Alimente Wight Loss
Anti Aging Anti Aging
Bio Metilare Bio Metilare
Cura De Slabire Cura De Slabire
Fitness Vitalitate Fitness Vitalitate
Hormoni Fat Burner Hormoni Fat Burner
Index Glicemic Index Glicemic
Obezitate Obezitate
Studii Internationale Studii Internationale
Shop Shop
Comanda fara Cookies nu este posibil!
Catalog Catalog Catalog
Acetil-L-Carnitina Acetil-L-Carnitina
Acetil-L-Carnitina Pro Acetil-L-Carnitina Pro
Acid Alfa Lipoic Acid Alfa Lipoic
Acid Alfa Lipoic Pro Acid Alfa Lipoic Pro
Artro Pro Artro Pro
Artro Pro Max Artro Pro Max
Carnosine Carnosine
Carnosine Pro Carnosine Pro
Ceai Verde Ceai Verde
Ceai Verde Pro Ceai Verde Pro
Ceai Verde Supreme Ceai Verde Supreme
Ceai Verde Supreme Pro Ceai Verde Supreme Pro
Chitosan Plus Chitosan Plus
Chitosan Plus Max Chitosan Plus Max
Chlorella Chlorella
Cintar de baie Cintar de baie
Coenzima Q10 Coenzima Q10
Coenzima Q10 Plus Coenzima Q10 Plus
Cura de Slabire Cura de Slabire
Cura de Slabire Max Cura de Slabire Max
Garlic Garlic
Glucozamin hidroclorit Glucozamin hidroclorit
Glucozamina sulfat Glucozamina sulfat
Homocisteina Formula Homocisteina Formula
Lecitina Suprema Lecitina Suprema
Multivitamine Minerale Multivitamine Minerale
Multivitamine Minerale+Luteina Multivitamine Minerale+Luteina
Multivitamine Minerale+Q10 Multivitamine Minerale+Q10
N-Acetilcisteina N-Acetilcisteina
N-Acetilcisteina Pro N-Acetilcisteina Pro
Palmier Pitic Pygeum Palmier Pitic Pygeum
Prostata Formula Prostata Formula
Set Cura de Alopecie Set Cura de Alopecie
Set Cura de Longevitate Set Cura de Longevitate
Set Cura de Slabire Set Cura de Slabire
Set aparat de masura Set aparat de masura
Silimarina Silimarina
Silimarina Pro Silimarina Pro
Spirulina Spirulina
Ulei de Peste Ulei de Peste
Urzica Urzica
Contact Contact
Termeni Termeni
Link Exchange Link Exchange
Oportunitate Oportunitate
Articol: Silimarina
Compozitie: 180 mg: Capsula
Prezentare: 1 Flacon cu 30 Capsule
Administrare: 1 Capsula pe zi
3-5 buc.: 9.80
6-8 buc.: 9.60
9-11 buc.: 9.40
12+ buc.: 9.20
Comanda fara Cookies nu este posibil!


1Silimarina Silimarina (Silybum Marianum) numit si Armurariu, extract standardizat: Silimarina 80%, 125 mgx30 buc.=10 lei noi, un antioxidant care neutralizeaza radicali liberi hidroxil (OH), oxigenul reactiv prin flavonoidul silibina, silibinina, si inhiba acidul arahidonic, moduleaza inflamatia articulara

2Silimarina Silimarina extract standardizat: Silimarina 80%, un remarcabil antioxidant si un protector hepatic





Silimarina (Silybum Marianum)- foto Familia: Asteraceae/Compositaea

Silimarina (Silybum Marianum)

3Silimarina Silimarina un antioxidant flavonoid, structura, functie si uz clinic

4Silimarina Efect stimulator Silimarina, Silibinina si Silicristina la celulele de rinichi

5Silimarina Silimarina impreuna cu izomerul sau Silibina cu efect la pacienti cu colecistectomie

6Silimarina Silimarina inhiba peroxidarea lipidica

7Silimarina Silimarina antioxidant efectiv in tratamentul de hiperinsulinemie la pacienti diabetici

8Silimarina Consumul de Silimarina in tratarea bolilor cronice hepatice

9Silimarina Silimarina in prevenirea de ciroza hepatica

10Silimarina Silimarina indicat in infectii de hepatite virale acute, studiu randomizat, dublu-orb, placebo controlat

11Silimarina Silimarina indicat in hepatite si hepatite cronice, studiu randomizat, dublu-orb, placebo controlat

12Silimarina Silimarina un antioxidant, flavonoid si lignani reduce valorile ale lipoproteinelor cu densitate joasa (colesterolul-LDL) la persoane cu hipercolesterolemie si hiperlipoproteinemie

13Silimarina Silimarina indicat in hiperinsulinemie la pacienti cu ciroza hepatica si diabet zaharat

14Silimarina Silimarina indicat in ciroza hepatica, studiu randomizat, dublu-orb, placebo controlat

15Silimarina Silimarina indicat in ciroza hepatica si hepatita alcolica, studiu randomizat, dublu-orb, placebo controlat

16Silimarina Silimarina reduce progresia de fibroza hepatica

17Silimarina Silmarina si Silibinina izomer al silimarinei inhiba invazia cancerului de plamin, reduce enzima urokinaza si metaloproteinaza matricial-2

18Silimarina Silimarina inhiba activitatea de telomeraza si antigenul specific prostatic, silibinina previne cancerul de prostata

19Silibina Silibina izomer al silimarinei cu efect antiproliferativ in maligne ginecologice si cancer mamar

20Silimarina Silimarina un natural antioxidant, flavonoid polifenolic inhiba carcinogeneza in colon

21Silimarina Silimarina ca flavonoid cu efect in intoxicatia de medicamente, studiu randomizat, dublu-orb, placebo controlat

22Silimarina Silimarina si Vitamina B complex in tratamentul de boli cronice hepatice, sistematic reviu cu meta analiza

23Silimarina Silimarina extract cu efect imunostimulator

24Silimarina Silimarina in tratamentul de Alzheimer

25Silimarina Silimarina cu cu efect la pacienti cu colestaza

26Silimarina Silimarina previne iradierea de raze ultraviolete UV-A

27Silimarina Acid alfa lipoic, Silimarina si Seleniu ca antioxidanti in tratamentul de hepatita C

28Silimarina Studiu comparativ intre Silimarina si complex de Silibina si Fosfatildilcolina in hepatita cronica activa, studiu randomizat, dublu-orb, placebo controlat

Complex de Silimarina si Lecitina cu Fosfatidilcolina 35 %



1. Mira ML, Azevedo MS, Manso C. The neutralization of hydroxyl radical by silibin, sorbinil and bendazac. Free Radic Res Commun 1987. 4:125-9.
- Valenzuela A, Guerra R, Videla LA. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: Comparison with butylated hydroxyanisole and butylated hydroxytoluene. Planta Med 1986. 6:438-40.
- Dehmlow C, Murawski N, de Groot H. Scavenging of reactive oxygen species and inhibition of arachidonic acid metabolism by silibinin in human cells. Life Sci 1996. 58:1591-600.
- Johnson VJ, He Q, Osuchowski MF, Sharma RP. Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulates inflammatory processes at high doses. Planta Medica. 2003;69(1):44-49.
2. Tenney L. Milk thistle: A remarkable flavonoid antioxidant and liver protectant. Pleasant Grove (UT): Woodlands Publications; 1995.
- Lapis, K., A. Jeney, et al. (1986). "Experimental studies on the effect of hepatoprotective compounds." Tokai J Exp Clin Med 11(Suppl): 135-45.
- Feher J, Lengyel G, Blazovics A. Oxidative stress in the liver and biliary tract diseases. Scand J Gastroenterol Suppl 1998. 228:38-46.
3. Miller AL. Antioxidant flavonoids: Structure, function and clinical usage. Altern Med Rev 1996. 1:103-11.
4. Sonnenbichler J et al, Stimulatory effects of silibinin and silicristin from the milk thistle
Silybum marianum on kidney cells, J Pharmacol Exp Ther 1999;290(3):1375-83
5. Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung 1992. 42:964-8.
6. Bindoli A, Cavallini L, Siliprandi N. Inhibitory action of silymarin of lipid peroxide formation in rat liver mitochondria and microsomes. Biochem Pharmacol 1977. 26:2405-9.
7. Velussi M, Cernigoi AM, De Monte A, et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997. 26:871-9.
8. Tanasescu, C., S. Petrea, et al. (1988). "Use of the Romanian product Silimarina in the treatment of chronic liver diseases." Med Interne 26(4): 311-22.
- Sarre H, Experience in the treatment of chronic hepatopathies with silymarin, Arzneim-Forsch 1971; 21:1209-12
- Luper S. A review of plants used in the treatment of liver disease: Part 1. Altern Med Rev 1998. 3:410-21.
- Bergner P. Botanical medicine: Silybum marianum and liver therapy. Townsend Lett Doctors 1988. 61-2:348-9.
- Hobbs C. Milk thistle: The liver herb. Loveland (CO): Interweave Press; 1994.
9. Mourelle, M., P. Muriel, et al. (1989). "Prevention of CCL4-induced liver cirrhosis by silymarin." Fundam Clin Pharmacol 3(3): 183-91.
10. Tkacz B, Dworniak D. Sylimarol in the treatment of acute viral hepatitis. Pol. Wiad Lek 1983. 36:613-6.
- Saba P, Mignani E, Pagliai, et al. Efficacy of silymarin treatment of acute virus hepatitis. Ita. Epatologia 1979. 25:277-81.
- Bode JC, Schmidt U, Durr HK. Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial author's transl. Ger. Med Klin 1977. 72:513-8.
- Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres author's transl. Ger. Med Klin 1978. 73:1060-5.
11. Giese LA. Milk thistle and the treatment of hepatitis. Gastroenterology Nursing. 2001;24(2):95-97.
- Kiesewetter E, Leodolter I, Thaler H. Results of two double-blind studies on the effect of silymarine in chronic hepatitis author's transl. Ger. Leber Magen Darm 1977. 7:318-23.
12. Svagera Z, Skottova N, Vana P, et al. Plasma lipoproteins in transport of silibinin, an antioxidant flavonolignan from Silybum marianum. Phytotherapy Research. 2003;17(5):524-530.
- Skottova N, Vecera R, Urbanek K, Vana P, Walterova D, Cvak L. Effects of polyphenolic fraction of silymarin on lipoprotein profile in rats fed cholesterol-rich diets. Pharmacology Research. 2003;47(1):17-26.
- Skottova N, Krecman V. Silymarin as a potential hypocholesterolaemic drug. Physiology Research. 1998;47(1):1-7.
- Krecman V, Silymarin inhibits the development of diet-induced hypercholesterolemia in rats, Planta Med 1998;64(2):138-42
- Krecman V, Skottova N, Walterova D, Ulrichova J, Simanek V. Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. Planta Medica. 1998;64(2):138-142.
- Somogyi A, Ecsedi GG, Blazovics A, Miskolczi K, Gergely P, Feher J. Short term treatment of type II sic with silymarin. Acta Medica Hungaria. 1989;46(4):289-295.
13. Maghrani M, Zeggwagh NA, Lemhadri A, El Amraoui M, Michel JB, Eddouks M. Study of the hypoglycaemic sic activity of Fraxinus excelsior and Silybum marianum in an animal model of type 1 diabetes mellitus. Journal of Ethnopharmacology. 2004;91(2-3):309-316.
- Velussi M, Cernigoi AM, Viezzoli L, et al. . Silymarin reduces hyperinsulinemia, malondialdehyde levels, and daily insulin need in cirrhotic diabetic patients. Curr Ther Res Clin Exp 1993. 53:535-45.
14. Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989. 9:105-13.
- Benda L, Dittrich H, Ferenzi P, et al. The influence of therapy with silymarin on the survival rate of patients with liver cirrhosis author's transl. Ger. Wien Klin Wochenschr 1980. 92:678-83.
- Salmi HA, Sarna S. Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 1982. 17:517-21.
- Muriel P, Mourelle M. The role of membrane composition in ATPase activities of cirrhotic rat liver: effect of silymarin. Journal of Applied Toxicology. 1990;10(4):281-284.
- Pares A, Plancs R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol 1998;28:615–21.
15. Trinchet JC, Coste T, Levy VG, et al. A randomized double blind trial of silymarin in 116 patients with alcoholic hepatitis. Fre. Gastroenterol Clin Biol 1989. 13:120-4.
- Pares A, Planas R, Torres M, Caballeria J, Viver JM, Acero D, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. Journal of Hepatology. 1998. 28(4):615-621.
- Feher J, Deak G, Muzes G, et al. Liver-protective action of silymarin therapy in chronic alcoholic liver diseases. Hun. Orv Hetil 1989. 130:2723-7.
- Bunout D, Hirsch S, Petermann M, et al. Controlled study of the effect of silymarin on alcoholic liver disease. Spa. Rev Med Chil 1992. 120:1370-5.
16. Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. Journal of Clinical Gastroenterology. 2003;37(4):336-339.
17. Chu SC, Chiou HL, Chen PN, Yang SF, Hsieh YS. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Molecular Carcinogens. 2004;40(3):143-149.
- Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. Biol Res 1994. 27:105-12.
18. Thelen P, Wuttke W, Jarry H, Grzmil M, Ringert RH. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells. Journal of Urology. 2004;171(5):1934-1938.
- Singh RP, Agarwal R. Prostate cancer prevention by silibinin. Current Cancer Drug Targets. 2004;4(1):1-11.
Zi X et al, Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention, Proc Natl Acad Sci U S A 1999;96(13):7490-5
- Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. Prostate. 2002;53(3):211-217.
- Dhanalakshmi S, Agarwal P, Glode LM, Agarwal R. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. International Journal of Cancer. 2003;106(5):699-705.
19. Scambia G, De Vincenzo R, Ranelletti FO, et al. Antiproliferative effect of silybin on gynaecological sic malignancies: synergism with cisplatin and doxorubicin. European Journal of Cancer. 1996;32A(5):877-882.
- Tyagi AK, Agarwal C, Chan DC, Agarwal R. Synergistic anti-cancer effects of silibinin with conventional cytotoxic agents doxorubicin, cisplatin and carboplatin against human breast carcinoma MCF-7 and MDA-MB468 cells. Oncology Reports. 2004;11(2):493-499.
- Zi X et al, Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins, Clin Cancer Res 1998;4(4):1055-64
20. Kohno H, Tanaka T, Kawabata K, Hirose Y, Sugie S, Tsuda H, Mori H. Silymarin, a naturally occurring polyphenolic antioxidant flavonoid, inhibits azoxymethane-induced colon carcinogenesis in male F344 rats. International Journal of Cancer. 2002;101(5):461-468.
21. Davila, J.C., Lenherr, A., and Acosta, D. "Protective Effect of Flavonoids on Drug-Induced Hepatotoxicity In Vitro." Toxicology. 1989. 57(3):267-86.
- Tuchweber B, Sieck R, Trost W. Prevention by silibinin of phalloidin induced hepatotoxicity. Toxicol Appl Pharmacol 1979;51:265–75.
- Hikino H, Kiso Y, Wagner H, Fiebig M. Antihepatotoxic actions of flavonolignans from Silybum marianum fruits. Planta Medica 1984;50:248–50.
- Garciapina, M.P., Perez-Alvarez, V., and Mourelle, M. "Silymarin Protects Against Paracetamol-Induced Lipid Peroxidation and Liver Damage." Journal of Applied Toxicology. 1992. 12(6):439-42.
- Faulstich H, Jahn W, Wieland T. Silibinin inhibition of amatoxin uptake in the perfused rat liver. Arzneim-Forsch Drug Res 1980;30:452–4.
- Palasciano G, Portinascasa P, Palmieri V, et al. The effect of silymarin on plasma levels of malondialdehyde in patients receiving long-term treatment with psychotropic drugs. Curr Ther Res 1994;S5:S37–45.
- Fintelmann V, Albert A. Double blind trial of silymarin sodium in toxic liver damage. Ger. Therapiewoche 1980. 30:5589-94.
- Magula D, Galisova Z, Iliev N, et al. Effect of silymarine and Fumaria alkaloids in the prophylaxis of drug-induced liver injury during antituberculotic treatment. Slo. Stud Pneumol Phtiseol 1996. 56:206-9.
22. Studlar M. Treatment of chronic liver disease with silymarin plus B-group vitamins. Ger. Therapiewoche 1985. 35:3375-8.
- Jacobs BP, Dennehy C, Ramirez G, Sapp J, Lawrence VA. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. American Journal of Medicine. 2002;113(6):506-515.
- Flora K, Hahn M, Rosen H, et al. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998. 93:139-43.
- Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-2063.
- Bode JC. . Re: Flora, et al. Silymarin for the therapy of liver disease. Am J Gastroenterol 1999. 94:545-6.
23. Wilasrusmee C, Kittur S, Shah G, Siddiqui J, Bruch D, Wilasrusmee S, Kittur DS. Immunostimulatory effect of Silybum Marianum (milk thistle) extract. Medical and Science Monitor. 2002;8(11):BR439-BR443.
24. Allain H, Shuck S, Lebreton S, et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with alzheimer's disease. Dement Geriatr Cogn Disord 1999. 10:181-5.
25. Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, et al. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: a study in vivo and in isolated hepatocyte couplets. Hepatology. 2001;34(2):329-339.
26. Li LH, Wu LJ, Zhou B, et al. Silymarin prevents UV irradiation-induced A375-S2 cell apoptosis. Biology and Pharmacology Bulletin. 2004;27(7):1031-1036.
- Dhanalakshmi S, Mallikarjuna GU, Singh RP, Agarwal R. Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis. 2004;25(8):1459-1465.
27. Berkson, B. M. (1999). "A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories." Med Klin 94 Suppl 3: 84-9.
28. Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study of the liver protective effect of silybin-phosphatidylcholine complex (idb1016) in chronic active hepatitis. International Journal of Clinical Pharmacology, Therapy, and Toxicology. 1993. 31(9):456-460.
- Barzaghi N, Crema F, Gatti G, et al. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990. 15:333-8.
- Marcelli R, Bizzoni P, Conte D, et al. Randomized controlled study of the efficacy and tolerability of a short course of IdB 1016 in the treatment of chronic persistent hepatitis. Eur Bull Drug Res 1992. 1:131-5.
- Orlando R, Fragasso A, Lampertico M, et al. . Silybin kinetics in patients with liver cirrhosis: A comparative study of silybin-phosphatidilcholine complex and silymarin. Med Sci Res 1990. 18:861-3.
- Pifferi G, Magistretti MJ. . A new bioavailable complex of silybin: Part II. Pharmacol Res 1993. 27:125-6.

  [ Top ]  
Copyright © 2005 by Design by NB